Aqueous Metabolite Trends for the Progression of Nonalcoholic Fatty Liver Disease in Female Bariatric Surgery Patients by Targeted 1H-NMR Metabolomics

Determining biomarkers and better characterizing the biochemical progression of nonalcoholic fatty liver disease (NAFLD) remains a clinical challenge. A targeted H-1-NMR study of serum, combined with clinical variables, detected and localized biomarkers to stages of NAFLD in morbidly obese females. Pre-surgery serum samples from 100 middle-aged, morbidly obese female subjects, grouped on gold-standard liver wedge biopsies (non-NAFLD; steatosis; and fibrosis) were collected, extracted, and analyzed in aqueous (D2O) buffer (H-1, 600 MHz). Profiled concentrations were subjected to exploratory statistical analysis. Metabolites varying significantly between the non-NAFLD and steatosis groups included the ketone bodies 3-hydroxybutyrate (& DARR;; p = 0.035) and acetone (& DARR;; p = 0.012), and also alanine (& UARR;; p = 0.004) and a putative pyruvate signal (& UARR;; p = 0.003). In contrast, the steatosis and fibrosis groups were characterized by 2-hydroxyisovalerate (& UARR;; p = 0.023), betaine (& DARR;; p = 0.008), hypoxanthine (& DARR;; p = 0.003), taurine (& DARR;; p = 0.001), 2-hydroxybutyrate (& UARR;; p = 0.045), 3-hydroxyisobutyrate (& UARR;; p = 0.046), and increasing medium chain fatty acids. Exploratory classification models with and without clinical variables exhibited overall success rates ca. 75-85%. In the study conditions, inhibition of fatty acid oxidation and disruption of the hepatic urea cycle are supported as early features of NAFLD that continue in fibrosis. In fibrosis, markers support inflammation, hepatocyte damage, and decreased liver function. Complementarity of NMR concentrations and clinical information in classification models is shown. A broader hypothesis that standard-of-care sera can yield metabolomic information is supported.

Automated summary

Determining biomarkers and characterizing the biochemical progression of NAFLD in morbidly obese females remains a clinical challenge. A targeted H-1-NMR study combined with clinical variables successfully detected and localized biomarkers to different stages of NAFLD. Early features of NAFLD include inhibition of fatty acid oxidation and disruption of the hepatic urea cycle, while markers in fibrosis support inflammation, hepatocyte damage, and decreased liver function.